Keros Therapeutics, Inc.
KROS Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.8%, EPS fell 90.8% and free cash flow grew 32.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KROS
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | |
|---|---|---|---|---|---|---|---|---|
Revenue |
244.06 | 3.55 | 0.15 | — | 20.10 | — | 10.00 | 10.00 |
Revenue Growth |
6,774.96% | 2,250.99% | (99.25%) | — | 101.00% | — | 0.00% | 0.00% |
Gross Profit |
244.06 | 3.55 | 0.15 | (1.61) | 20.10 | (0.60) | 10.00 | — |
R&D Expenses |
129.64 | 173.63 | 135.26 | 87.27 | 55.14 | 33.86 | 17.38 | 10.11 |
SG&A Expenses |
46.85 | 40.75 | 34.83 | 27.53 | 21.33 | 12.80 | 3.18 | 1.28 |
Operating Income |
67.57 | (210.83) | (169.94) | (114.79) | (56.37) | (46.66) | (10.56) | — |
Non-operating Income/Expense |
24.33 | 23.78 | 16.95 | 10.11 | (0.36) | 1.12 | (1.77) | 0.69 |
Non-operating Interest Expenses |
— | — | — | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| 91.90 | (187.05) | (152.99) | (104.68) | (56.73) | (45.53) | (12.34) | (1.08) | |
Income Tax Provision |
4.88 | 0.30 | — | — | 2.01 | (0.17) | — | 0.26 |
Income after Tax |
87.01 | (187.35) | (152.99) | (104.68) | (58.74) | (45.36) | (12.34) | — |
Dividends (Preferred) |
— | — | — | — | — | — | 1.80 | — |
Net Income Common |
87.01 | (187.35) | (152.99) | (104.68) | (58.74) | (45.36) | (14.14) | (2.35) |
EPS (Basic) |
2.34 | (5.00) | (5.20) | (4.15) | (2.52) | (2.93) | (5.30) | (0.12) |
EPS (Diluted) |
2.30 | (5.00) | (5.20) | (4.15) | (2.52) | (2.93) | (5.30) | (0.12) |
Shares (Basic, Weighted) |
37.22 | 37.44 | 29.45 | 25.24 | 23.33 | 15.51 | 2.33 | 18.94 |
Shares (Diluted, Weighted) |
37.86 | 37.44 | 29.45 | 25.24 | 23.33 | 15.51 | 2.33 | 18.94 |
Gross Margin |
100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% | 0.00% |
EBIT Margin |
27.69% | (5,938.96%) | (112,543.71%) | 0.00% | (280.46%) | 0.00% | (105.63%) | (33.82%) |
EBT margin |
37.65% | (5,269.10%) | (101,319.21%) | 0.00% | (282.25%) | 0.00% | (123.36%) | (10.78%) |
Net Profit Margin |
35.65% | (5,277.55%) | (101,319.21%) | 0.00% | (292.26%) | 0.00% | (141.36%) | (23.46%) |
Free Cash Flow Margin |
43.41% | (4,585.92%) | (84,087.42%) | 0.00% | (314.29%) | 0.00% | (162.69%) | 70.42% |
EBITDA |
69.08 | (209.60) | (169.13) | (114.12) | (55.99) | (46.38) | (10.35) | (1.39) |
EBIT |
67.57 | (210.83) | (169.94) | (114.79) | (56.37) | (46.66) | (10.56) | (3.38) |
Income from Continuous Operations |
87.01 | (187.35) | (152.99) | (104.68) | (58.74) | (45.36) | (12.34) | — |
Consolidated Net Income/Loss |
87.01 | (187.35) | (152.99) | (104.68) | (58.74) | (45.36) | (12.34) | (1.33) |
EPS (Basic, from Continuous Ops) |
2.34 | (5.00) | (5.20) | (4.15) | (2.52) | (2.93) | (5.30) | — |
EPS (Basic, Consolidated) |
2.34 | (5.00) | (5.20) | (4.15) | (2.52) | (2.93) | (5.30) | — |
EPS (Diluted, from Cont. Ops) |
2.30 | (5.00) | (5.20) | (4.15) | (2.52) | (2.93) | (5.30) | — |
Shares (Diluted, Average) |
37.86 | 37.44 | 29.45 | 25.24 | 23.33 | 15.51 | — | — |
EPS (Diluted, Consolidated) |
2.30 | (5.00) | (5.20) | (4.15) | (2.52) | (2.93) | (5.30) | — |
EBITDA Margin |
28.30% | (5,904.34%) | (112,003.97%) | 0.00% | (278.58%) | 0.00% | (103.55%) | (13.87%) |
Operating Cash Flow Margin |
44.05% | (4,531.52%) | (82,455.63%) | 0.00% | (309.19%) | 0.00% | (159.98%) | 70.42% |